TP53 and Thrombocytopenia: Mdm2-p53 inhibitors still have many side effects, including dose being limited by myelosuppression especially thrombocytopenia, metabolic disturbances, and gastrointestinal toxicities (Iancu-Rubin et al. 2014; Konopleva et al. 2020; Mahfoudhi et al. 2016).